Table 1:
Demographic, clinical, and neuroimaging features in patients with PSP-P, PSP-RS, PD, and healthy controls
| PSP-P (n = 9) | PSP-RS (n = 21) | PD (n = 20) | HC (n = 30) | |
|---|---|---|---|---|
| Age (mean) (yr) | 70.1 ± 4.8 | 71.9 ± 5.9 | 66.2 ± 3.0 | 67.2 ± 7.2 |
| Sex, % male | 100% | 57% | 50% | 47% |
| Disease duration (mean) (yr) | 6.3 ± 3.7 | 3.1 ± 1.4 | 7.5 ± 3.7 | – |
| MMSE (mean) | 22.1 ± 3.6 | 19.0 ± 5.4 | 23.2 ± 3.3 | – |
| UPDRS-III (mean) | 22.8 ± 17.7 | 39.3 ± 7.7 | 27.1 ± 9.1 | – |
| HY (mean) | 2.9 ± 0.7 | 3.4 ± 0.8 | 2.2 ± 0.5 | – |
| SCP right | ||||
| Volume (No. of voxels) (mean) | 5652 ± 1172 | 5282 ± 753 | 6907 ± 1306 | 6569 ± 944 |
| FA (mean) | 0.44 ± 0.05 | 0.40 ± 0.05 | 0.48 ± 0.04 | 0.45 ± 0.02 |
| MD (×10−3 mm2/s) (mean) | 0.873 ± 0.06 | 0.949 ± 0.170 | 0.851 ± 0.089 | 0.833 ± 0.031 |
| SCP left | ||||
| Volume (No. of voxels) (mean) | 5315 ± 1121 | 4812 ± 701 | 6369 ± 1205 | 5961 ± 894 |
| FA (mean) | 0.44 ± 0.04 | 0.39 ± 0.05 | 0.47 ± 0.04 | 0.45 ± 0.02 |
| MD (×10−3 mm2/s (mean) | 0.895 ± 0.061 | 0.974 ± 0.074 | 0.874 ± 0.066 | 0.857 ± 0.023 |
Note:—HC indicates healthy controls; MMSE, Mini-Mental State Examination; UPDRS-III, Unified Parkinson's Disease Rating Scale–Motor Examination; HY, Hohen and Yahr score.